We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » HHS ANTHRAX VACCINE DELAY THREATENS COMPANY, SAYS VAXGEN

HHS ANTHRAX VACCINE DELAY THREATENS COMPANY, SAYS VAXGEN

May 12, 2006

Delivery to the federal government of the anthrax vaccine being developed by VaxGen, originally expected to occur by the end of the year, now will be pushed until at least late 2007, delivering a heavy fiscal blow to the financially struggling company, a VaxGen spokesman said.

HHS on May 10 confirmed its contract, first awarded in November 2004 under the BioShield program, to purchase 75 million doses of the vaccine for the Strategic National Stockpile at a price tag of $877.5 million (DID, Nov 8, 2004). However, VaxGen said, HHS at the same time modified its contract to require new clinical and nonclinical studies that will delay delivery of the vaccine until at least the end of 2007 or, more likely, early 2008. The company also noted that the changes were made without formal negotiation with HHS.

VaxGen said that since it will not be paid until the vaccine is delivered, these new requirements will increase its expenses, a factor not addressed by the contract modifications. Because of the new delay, "We do not have enough money to fund the company" through the anticipated delivery date of the vaccine, Lance Ignon, VaxGen's vice president for corporate affairs, said.

The company last reported it had $35 million in cash reserves on Feb. 10, directly following a nearly $27 million dollar sale of common stock.

"We will have to raise more money," Ignon said. "[The delay] makes that more difficult."

Company executives said they will meet with members of Congress and senior decisionmakers at HHS to try to get the contract modifications rescinded. If that is not successful, they said there is a legal team exploring possible ways to be compensated for the additional expenses under terms of the Federal Acquisition Regulation, the basic rulebook on government contracts. (http://www.fdanews.com/did/5_94/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing